UW Department of Pharmacy Faculty Meeting Agenda  
December 20, 2021 | 9:00 to 10:00 am  
Zoom | Conference URL: [https://washington.zoom.us/j/860946066](https://washington.zoom.us/j/860946066)  
Meeting ID: 860 946 066 | Zoom Phone Number: +1 197 247 1195

<table>
<thead>
<tr>
<th>Topic/ Business</th>
<th>Presenter</th>
<th>Approx. Time</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Welcome and Announcements</td>
<td>White</td>
<td>10 min</td>
<td></td>
</tr>
<tr>
<td>Approval of Minutes (November 2021 meeting) [Vote Requested]</td>
<td>White</td>
<td>5 min</td>
<td>2</td>
</tr>
<tr>
<td>Frank Tverdek Clinical Faculty Appointment [Vote Requested]</td>
<td>Danielson</td>
<td>5 min</td>
<td>4</td>
</tr>
<tr>
<td>OPPE and EE Updates</td>
<td>Danielson</td>
<td>10 min</td>
<td></td>
</tr>
<tr>
<td>Graduate Program Review Virtual Site Visit January 7, 10, 11, 2022</td>
<td>Stergachis</td>
<td>5 min</td>
<td>14</td>
</tr>
<tr>
<td>Open Forum</td>
<td>White</td>
<td>25 min</td>
<td></td>
</tr>
</tbody>
</table>
Meeting called by:  H. Steve White  
Note taker:  Katherine Painter


Minutes

Agenda item:  Welcome and Announcements  
Presenter:  H. Steve White

Discussion:
Steve White welcomed faculty and staff and provided updates about the current Quarter.

Agenda item:  Approval of Minutes (October 2021)  
[Vote Requested]  
Presenter:  H. Steve White

Discussion:
Requested motion of October minutes. No questions or comments posed. Minutes for October meeting were unanimously approved, no objections or abstentions.

Agenda item:  Josh Gener Affiliate Assistant Professor Appointment  
[Vote Requested]  
Presenter:  Dave Veenstra

Discussion:
Requested motion of appointing Josh Gener to Affiliate Assistant Professor. No questions or comments posed. Motion to appoint Josh was unanimously approved, no objections or abstentions.

Agenda item:  Curriculum Committee Updates  
Presenter:  Ryan Hansen

Discussion:
Ryan Hansen noted registration is ongoing and that students are asking about course recordings to accommodate any conflicts. The first cohort of the Purple Curriculum is entering their last didactic quarter and preparing for APPEs. The Curriculum Committee is appointing a group of faculty to organize the continuous quality improvement of the curriculum. This includes working with Course Masters who teach within a series and then as a group to coordinate updates and changes between series in an organized fashion. A Series Lead group will formalize the work as we head toward accreditation and have the first graduating class of the Purple Curriculum.

Reminder that the time schedule for each quarter occurs between 4-6 months ahead of the quarter in order for classroom services room scheduling to occur.
Discussion:

Steve White provided an overview of the purpose of the SOP-wide Promotion and Tenure Guidelines. The official work group documenting these guidelines are members of the SOP Promotion and Tenure Committee, which includes Ken Thummel, Allan Rettie, and Beth Devine. The Committee asked Lingtak-Neander Chan to assist and corroborate their guidelines with the guidelines the DOP has been working on. Steve shared the draft document with the DOP faculty in the week prior to this meeting. The faculty were asked to submit questions and comments in writing. After review, Steve and Lingtak led an open discussion with faculty addressing comments they submitted. Lingtak will incorporate edits and changes based on this meeting to create an updated version, which will be emailed to Ken for the P&T Committee to review. The final draft will then be reviewed by the SOP Faculty Council.

Discussion:

CHOICE Institute Updates:

- Dr. Jing Li from Cornell, the top candidate for the open Assistant Professor in Health Economics has accepted our offer and will join our faculty effective August 1, 2022.
- CHOICE received 75 PhD applications, the highest in the past 10 years. The selection process will continue over the next month.
- Six new PharmD-MS fellows were recruited to start in the summer of 2022.

Discussion:

No further questions or comments posed.
December 9, 2021

H. Steve White, RPh, Ph.D
Chair and Professor
Department of Pharmacy
University of Washington
Box 357630
Seattle, WA 98195

RE: Tverdek, Frank

Dear Steve:

I would like to nominate Frank Tverdek for a courtesy appointment as a Clinical Associate Professor in the Department of Pharmacy.

Dr. Tverdek has been employed at UWMC's Seattle Cancer Care Alliance as an Inpatient Antimicrobial Stewardship Pharmacist since 2020. In teaching our PharmD students at this site, Dr. Tverdek is providing an extremely valuable, yet uncompensated, service to our program and to the School.

Dr. Tverdek has precepted UW students informally in few ways. He co-precepted Amanda Fairbanks for a clinical research project and has provided several shadow opportunities for IPPE students at UWMC. Dr. Tverdek is most interested in working with our students on quality improvement and research type projects related to infectious diseases and antimicrobial stewardship.

I ask that this candidate’s credentials be presented for review and vote at the next faculty meeting. Please notify me of the outcome so that we can proceed with the appointment.

Sincerely,

Jennifer Danielson, PharmD, MBA, CDE
Director Experiential Education, Introductory Practice
Associate Professor
University of Washington School of Pharmacy
Jendan@uw.edu
206-543-1924
I would like to start the process for Clinical Faculty Appointment consideration.

I am currently a clinical pharmacist with Infectious Diseases training. I work at UW- Montlake hospital as SCCA's inpatient antimicrobial stewardship pharmacist.

I have precepted UW students informally in several ways thus far. I co-precepted a UW student on a clinical research project (Amanda Fairbanks). She will be presenting it as a poster at the upcoming ID Week in October. I have also provided several shadowing opportunities for IPPE students as they rotate onsite at UW Montlake. (Most recently, UW student Nathaniel Crawford.)

I have interest in working with UW students. Specifically, we have many quality improvement and research type projects related to Infectious Diseases and Antimicrobial Stewardship. I would love to work with students who are looking to get their feet wet in these areas, whether that be ID or research/QI.

I am also invested in precepting our UW Pharmacy residents, with several rotations each year.

Lastly, I would be interested if ever there were guest lecture opportunities on relevant topics.

I have added my manager, Mary Chi, on this email.

Thank you,

Frank P. Tverdek, PharmD

Infectious Diseases & Antimicrobial Stewardship Pharmacist
Pronouns: he/him/his

Phone: (206) 598-4591
Pager: (206) 615-8327
ftverdek@seattlecca.org
WORK EXPERIENCE

2020- Current
Antimicrobial Stewardship Pharmacist - Seattle Cancer Care Alliance; University of Washington Medical Center: Seattle, WA
Co-lead SCCA inpatient antimicrobial stewardship efforts along with SCCA Infectious Diseases department. Provide clinical rounding services with the Infectious Diseases consult team as well as perform day to day antimicrobial stewardship activities. Conduct/lead clinical research and quality improvement projects related to antimicrobials. Precept students and residents in variety of roles: rotations, research projects, etc. Affiliated with University of Washington and Fred Hutchinson Cancer Research Center. [Full-time; 40-60hrs/week]

2016- 2020
Clinical Pharmacy Manager - Department of Clinical Pharmacy Programs; University of Texas, M.D. Anderson Cancer Center: Houston, TX
Manage 15 clinical pharmacy specialists in the following areas: Infectious Diseases, Internal Medicine, and Genitourinary Cancer. Lead antimicrobial stewardship through management of the hospital's Antimicrobial Stewardship Program in concert with Infectious Diseases department. Provide 1-2 days per week clinical services in relation to Infectious Diseases. Serve as program coordinator for PGY2 Infectious Diseases residency. Conduct/lead clinical research and quality improvement projects related to antimicrobials. [Full-time; 40-60hrs/week]

2011- 2016
Clinical Pharmacy Specialist- Infectious Diseases; University of Texas, M.D. Anderson Cancer Center : Houston, TX
Re-established the hospital's Infectious Diseases clinical pharmacy specialist position which had been vacant for three years. Collaborate on daily rounds with inpatient Leukemia ID consult team. Perform antimicrobial stewardship through management of the hospital's Antimicrobial Stewardship Program in concert with Infectious Diseases department. Manage antibiotic formulary issues such as new drug monographs, restriction protocols, and drug allocation in drug shortage situations. Precept pharmacy students, PGY1 Pharmacy Residents, and PGY2 Critical Care/Oncology residents. Conduct clinical research and quality improvement projects related to antimicrobials. [Full-time; 40-60hrs/week]

2008- 2011
Infectious Diseases Clinical Pharmacist; St. Louis University Hospital (SLUH) - Tenet Healthcare: St. Louis, MO
Re-established the hospital's Infectious Diseases clinical pharmacist position which had been vacant for two years. Collaborate on daily rounds with inpatient ID consult team. Precepted and provided consultation to clinicians in the Infectious Diseases clinic. Managed antibiotic formulary issues such as new drug monographs, restriction protocols, and drug allocation in drug shortage situations. Designed database for tracking antibiotic utilization and susceptibility trends. Precepted pharmacy students, PGY1 Pharmacy Residents, and PGY2 Critical Care residents. Performed order entry/dispensing functions and staff the IV room as needed by pharmacy department. [Full-time; 40-60hrs/week]

2007- 2008
Infectious Diseases Specialty Resident; Midwestern University – Chicago College of Pharmacy
PGY-2 pharmacy residency specializing in Infectious Diseases; practice site Rush University Medical Center. Designed and implemented a new antimicrobial stewardship program with aid of preceptors. Completed formal teaching/preceptoring program. [Full-time; 40-60hrs/week]
2007-2008  **Staff Pharmacist; Rush University Medical Center: Chicago, IL**
Worked as in-patient hospital pharmacist one weekend per month during residency training. Performed medication verification, medication dispensing, pharmaco-kinetic monitoring, IV to PO interventions, and drug information. Utilized EPIC computer system. [Part-time; 16 hours/month]

2006-2007  **Pharmacy Practice Resident; Rush University Medical Center: Chicago, IL**
PGY-1 residency with emphasis on adult in-patient care. [Full-time; 40-60hrs/week]

2002-2006  **Pharmacy Intern; Walgreens: Oak Brook, IL**
Worked in community pharmacy part-time (15-30hrs) during school, full-time over summer breaks.

2001-2002  **Student Researcher; University of Illinois at Urbana-Champaign (Cheng/Devries Lab)**
Performed research required to meet goals of animal physiology research project, managed/allocated project funds, analyzed data, and submitted final report for poster session at local meeting. [Part-time; 20 hours/month]

1999-2001  **Research Assistant; University of Illinois at Urbana-Champaign (Cheng/Devries Lab)**
Performed various research tasks related to graduate, post-graduate, and biology/ecology departmental research projects. [Part-time; 20 hours/month]

**EDUCATION**

2007-2008  Midwestern University - Chicago College of Pharmacy, Downers Grove, IL
*PGY-2 Residency; Specialty: Infectious Diseases*
*Program Director: Christopher Crank PharmD, Kendra Atkinson PharmD*

2006-2007  Rush University Medical Center (RUMC), Chicago, IL
*PGY-1 Pharmacy Practice Residency*
*Program Director: Nora Flint PharmD*

2002-2006  Midwestern University - Chicago College of Pharmacy, Downers Grove, IL
*Graduation: March 2006; Pharm.D.*

1998-2002  University of Illinois at Urbana-Champaign, UIUC
*Major: Molecular and Integrative Physiology*
*Minor: Chemistry*
*Graduation: May 2002; B.S.*

**PUBLICATIONS**


**PRESENTATIONS**

**Breakthrough Fungal Infections in the HCT Patient.** Reviewed literature related to breakthrough fungal infections as stratified by type of antifungal prophylaxis in patients who received a HCT. Transplantation and Cellular Therapy (TCT) Conference. Orlando, FL 3/20 [oral presentation]

**Interventions, Strategies and Barriers to Stewardship in the Immunocompromised Patient.** Described the risk of antimicrobial resistance, challenges to stewardship, and successes as related to patients with cancer and transplantation. Making a Difference in Infectious Diseases (MAD-ID). Orlando, FL. 5/18 [oral presentation]

**Automating Antimicrobial Stewardship.** Reviewed literature related to novel methods of automation of antimicrobial stewardship efforts through the use of technology. Related institution successes in automating an antimicrobial time-out. Inaugural Texas Medical Center Antimicrobial Resistance and Stewardship Conference. Houston, TX. 1/18 [oral presentation]

**Antimicrobial Stewardship in the Immunocompromised Population.** Discussed evidence based approach to stewardship in this vulnerable patient population. Co-presented with Patrick McDaneld, PharmD. Vizient Webinar. 11/17 [oral presentation]

**Antimicrobial Stewardship.** Discussed implementation of stewardship activities and compliance with Joint Commission standards related to antimicrobial stewardship. 6/17; University of Texas Hospital Pharmacy Practice Seminar. Houston, TX [oral presentation]

**Antimicrobial Stewardship: Compliance with Joint Commission Standard.** Discussed implementation of stewardship activities and compliance with Joint Commission standards related to antimicrobial stewardship. 3/17; Comprehensive Cancer Center Infection Control Conference (C3IC.) Houston, TX [oral presentation]
Update on New Antimicrobials and Diagnostics. Discussed recently FDA approved antimicrobials and their role in therapy. Discussed the role of rapid diagnostics and their impact on treatment of infection. 10/15; Texas SCCM Symposium. San Antonio, TX. [oral presentation]

Evaluation of Beta-lactam Duration on the Incidence of ESBL E. Coli or Klebsiella Bacteremia in Cancer Patients. Discussed findings of clinical research project regarding risk factors for ESBL bacteremia. 9/15; ICAAC Annual Meeting. San Diego, CA. [oral presentation]

Antibiotic Allergy. Infectious Diseases Fellow Core Curriculum. Discussed implications of antimicrobial allergy in the management of infectious diseases. 2/13; 2/14; Houston, TX. [oral presentation]

QT Prolongation: Antimicrobials. Discussed clinical impact of various antimicrobials on the risk of prolonging the QT interval. Grand Rounds. MD Anderson Cancer Center. 11/12. Houston, TX. [oral presentation]


Antimicrobial Stewardship in Cancer Patients: How and Why? Presented the case for stewardship in the immunocompromised patient population. 16th Annual MD Anderson Supportive Care Conference. 3/12; Houston, TX. [oral presentation]

Aminoglycosides- Dosing and Rationale for Use: Discussed pharmacokinetics of aminoglycosides, various dosing strategies, and safety concerns. Recommended an algorithm for working through aminoglycoside related issues in a patient. 10/10; Presented at SLUH Department of Pharmacy Clinical Pearls Meeting. [oral presentation]

Vancomycin Initiative Data Presentation: Presented outcome of a vancomycin quality improvement project regarding changes in laboratory reporting of vancomycin level interpretation. 9/09; Presented at SLUH Department of Pharmacy Weekly Meeting. [oral presentation]

Microbiology as it Relates to Pharmacy: Described the processing of microbial specimens and the culmination of the process in an organism’s susceptibility profile. Discussed automated vs manual susceptibility testing as well as the use of “expert” interpretation systems. 2/10; Presented at SLUH Department of Pharmacy Clinical Pearls Meeting. [oral presentation]

Clinical Relevance of Beta-Lactamases: Defined and described beta-lactamase terminology. Compared and contrasted beta-lactamases; i.e. KPC vs. ESBL vs. AmpC. Discussed therapeutic options based on patient specific factors, site of infection, and type of resistance pattern. 3/09; Presented at SLUH Department of Pharmacy Clinical Pearls Meeting. [oral presentation]

Clinical Evaluation of Piperacillin/tazobactam MICs for Treatment of Pseudomonas aeruginosa. Discussed PGY-2 research results. 4/08; Presented at Great Lakes Residency Conference. [oral presentation]

Cefepime Neurotoxicity: With focus on beta-lactam neurotoxicity, physiological basis of event, and prevalence and variations in risk between agents. Also, reviewed cefepime literature relating to neurotoxicity. 11/07; Presented at RUMC/Stroger ID Grand Rounds. [oral presentation]

Clinical Relevance of Vancomycin Minimum Inhibitory Concentrations in the Treatment of Methicillin-Resistant Staphylococcus aureus: Discussed characterization of various phenotypic presentations of resistance, increasing prevalence of resistance, and treatment options for infections in
which vancomycin may be sub-optimal. 10/07; Presented to Midwestern University, College of Pharmacy faculty. [oral presentation]

Assessment of the Antimicrobial Treatment of Hospital and Ventilator Associated Pneumonia at a University Hospital: Discussed PGY-1 research results. 4/07; Presented at Great Lakes Residency Conference. [oral presentation]

COMMITTEE INVOLVEMENT

Society of Infectious Diseases Pharmacists (SIDP) – Strategic Planning Committee: Currently chair 2021; assistant chair 2020; member 2019, 2018. Monitor the organization’s activities for alignment to the strategic plan. In 2021, facilitated a revision of the current strategic plan which was previously implemented in 2017. (2018 to present)

U.W. Medicine Antimicrobial Stewardship Committee: Collaborate with other UW pharmacists on a variety of antimicrobial stewardship projects. Involved in creating and revising current antimicrobial related guidelines. Devising antimicrobial stewardship interventions. Collecting, analyzing and creating interventional activities based on antimicrobial stewardship related data. (4/20 - present)

Houston Antimicrobial Stewardship Executive Committee: Advise the Houston Health Department on antimicrobial stewardship related matters affecting Houston residents. Collaborate with city hospitals on antimicrobial stewardship related projects. (6/17- 3/20)

M.D. Anderson Antimicrobial Stewardship Team: Co-chair-pharmacy leader for the committee. Created and implemented institutional policies regarding antimicrobial stewardship activities. Created and revised antimicrobial algorithms and order sets. Oversaw expansion of the antimicrobial stewardship program to various services. Designed antimicrobial electronic alert system. Devised method for providing antimicrobial stewardship to the infectious diseases attending physicians. Designed methods for tracking compliance with stewardship policies as well as system for tracking antimicrobial utilization trends. (4/11 – 3/20)

M.D. Anderson Infection Control Committee: Provided pharmacy insight to the multidisciplinary committee. Also updated other members regarding antimicrobial stewardship within the institution. (5/11 - 3/20)

PGY2 Infectious Diseases Resident Advisory Committee: Served as program coordinator for this new program. (7/18 –3/20)

PGY2 Health Systems Pharmacy Administration Resident Advisory Committee: Monitored resident progress throughout the year, as well as made recommendations for improvement of the residents and program. (7/15 –3/20)

M.D. Anderson Echinocandin Workgroup: Co-chair; Led efforts aimed at evaluation of echinocandin use in the institution. Oversaw decision to choose caspofungin as formulary choice. Managed implementation of formulary change/restriction of micafungin and anidulafungin. (7/12-6/13)

PGY2 Critical Care Resident Advisory Committee: Monitored resident progress throughout the year, as well as made recommendations for improvement of the residents and program. (7/11 –7/16)

PGY1 Residency Resident Advisory Council: Monitored resident progress throughout the year, as well as made recommendations for improvement of the residents and program. (7/12 – 7/14)
Tenet Anti-infective Guideline Development Subcommittee: Chaired committee; Developed multiple guideline related documents aimed at arming front-line pharmacists with tools to deal with antimicrobial stewardship concerns. (6/10-10/10)

Tenet Corporate Anti-infective Committee: Discussed and strategized corporate infectious diseases related initiatives. Focus was primarily on antibiotic utilization and issues relating to various vendor contracts. Provided clinical infectious diseases perspective to a variety of health care workers and administration who also take part in committee work. (12/08-3/11)

SLUH Infection Control Committee: Completed multi-drug resistant organism (MDRO) project related to JCAHO patient safety goal. Designed database tracking antibiogram data over previous 5 years. Designed method and database for tracking antibiotic utilization as related to charge data over previous 5 years. Facilitated project aimed at assessing role of anaerobic therapy in the treatment of aspiration pneumonia in surgery critical care units. (10/08 – 3/11)

SLUH PTNT Committee: Prepared monograph and recommendations for formulary addition of the following agents: ertapenem, cefpodoxime, tigecycline, darunavir, maraviroc, etravirine, raltegravir, and micafungin. Led initiative to convert from caspofungin to micafungin as formulary agent. Managed restriction program related to tigecycline use. Perform “gate-keeper” function in times of limited supply of antibiotics due to shortages; i.e. acyclovir, amikacin, trimethoprim/sulfamethoxazole. (9/08 – 3/11)

Hospital Disaster Vaccination Response Team (HDVRT): Managed stockpile of Influenza vaccine, provided drug information, and counseled vaccine recipients during mass immunization drill of ~700 healthcare workers within Rush University Medical Center. (11/07)

Anti-Infective Subcommittee of Pharmacy and Therapeutics Committee (RUMC): Maintained current anti-infective formulary, discussed proposed additions to the formulary, engaged in drug utilization evaluation (DUE) for anti-infectives, maintained list of restricted anti-infective medications. (7/07-7/09)

AWARDS

University of Texas Houston/Galveston Region Outstanding Clinical Preceptor Award 2013-2014

LICENSE AND CERTIFICATION

Board Certified Pharmacotherapy Specialist (BCPS) Since 2009; with Added Qualifications in Infectious Diseases (AQ-ID) since 2017

Washington Pharmacist License # PH60932070

Illinois Pharmacist License # 051.291154

Texas Pharmacist License # 49927

Certified in Medical Quality (CMQ) since 2018

Basic Life Support (BLS) American Heart Association Certified since 7/2006

-References Available Upon Request-

LAST UPDATED: August 2021
UNIVERSITY OF WASHINGTON
School of Pharmacy
Graduate Program Academic Review
Virtual Site Visit Agenda
January 7, 10 & 11, 2022
Self-Study_School of Pharmacy Graduate Program Review_19 Nov 2021.pdf

Day ‘Zero’:
Friday, January 7th
https://washington.zoom.us/j/98766428021
10:00 – 10:45 a.m.

Meeting with Chairs and Associate Dean
Andy Stergachis, Professor and Associate Dean of Research & Graduate Programs
William Atkins, Professor and Chair, Medicinal Chemistry
Nina Isoherranen, Professor and Chair, Pharmaceutics
H. Steve White, Professor and Chair, Pharmacy

10:45 – 11:30 a.m.

Meeting with Graduate Program Directors and Advisors
Josh Carlson, Associate Professor, Department of Pharmacy
Abhinav Nath, Associate Professor, Department of Medicinal Chemistry
Shiu-Loc Hu, Professor, Department of Pharmaceutics
Marina Gano, Graduate Program & Operations Manager, Department of Pharmacy
Sarah Lenti, Graduate Program Operations Specialist, Department of Medicinal Chemistry
Elsa Hagos, Department of Pharmaceutics
Andy Stergachis, Professor and Associate Dean of Research & Graduate Programs

Day One:
Monday, January 10th
https://washington.zoom.us/j/92237976207
8:00 – 9:00 a.m.

Meeting with School’s Faculty Council Chair, Past Chair & School-Wide Committee Chairs
Rheem Totah, Professor, Faculty Council Chair
Sharon Wu, Clinical Assistant Professor, Faculty Council Member
Qingcheng Mao, Associate Professor, Faculty Council Past Chair
Kelly Campbell & Abhinav Nath, Diversity, Equity, and Inclusion Committee Co-Chairs
Libin Xu & Ryan Hansen, Curriculum Committee, Co-Chairs
Andy Stergachis, Professor, Senior Leadership Committee Chair
9:00 – 9:45 a.m.  Meeting with Assistant and Associate Professors

9:45 – 10:00 a.m.  Break

10:00 – 10:45 a.m.  Meeting with Full Professors

10:45 – 11:30 a.m.  Meeting with Master’s Degree Students –
   Ellen Riddle, PCEUT
   Tim Tsang, PCEUT
   Tommy Majda, CHOICE
   Justin Nedzesky, CHOICE
   Joseph Yang, CHOICE

11:30 – 12:15 p.m.  Lunch

12:15 – 1:00 p.m.  Meeting with PhD Students –
   Yilin Chen, CHOICE
   Woojung Lee, CHOICE
   Enrique M Saldarriaga, CHOICE
   Amy Li, MEDCHEM
   Vanessa Lopez, MEDCHEM
   Jonathan Palmer, MEDCHEM
   Taeyoon Jung, MEDCHEM
   Nathan Alade, PCEUT
   Anish Mahadeo, PCEUT
   Leticia Salvador-Vieira, PCEUT
   Cindy Zhang, PCEUT

1:00 – 1:30 p.m.  Meeting with Postdoctoral Fellows
   Michelle Guignet, DOP
   Ogochukwu Amaeze, PCEUT
   Flavia Storelli, PCEUT
   Ryan Seguin, MEDCHEM
   Yuanyuan Shi, MEDCHEM

1:30 – 2:00 p.m.  Meeting with Finance and Administration & Advancement
   Kelly Campbell, Assistant Dean of Finance and Administration
   Claire Forster, Associate Dean for Advancement and Corporate Relations
Day Two:
Tuesday, January 11th

https://washington.zoom.us/j/93635250975

8:00 – 9:30 a.m. Meeting with Research Track Faculty and Research Programs, Centers, Institute
- Research Track Faculty: (TBD)
- Research Programs, Centers, Institute Leaders from:
  - Institute for Innovative Pharmacy Practice (I2P2) (Jennifer Bacci)
  - Pharmacogenomics Research Network (PGRN) (Kenneth Thummel)
  - Plein Center for Geriatric Pharmacy Research, Education and Outreach (Shelly Gray)
  - The Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute (Anirban Basu)
  - Global Medicines Program (Andy Stergachis)
  - Program on Pharmacokinetics of Drugs of Abuse during Pregnancy (UWPKDAP) (Jashvant Unadkat)
  - Targeted Long-Acting Combination Antiretroviral Therapy Program (TLC-ART) (Rodney Ho)
  - Research Affiliate Program on Transporters (UWRAPT) (Jashvant Unadkat)
  - The Washington Entrepreneurial Research Evaluation and Commercialization Hub (WE-REACH) (Rodney Ho)
  - Drug Interactions Solutions (Isabelle Ragueneau-Majlessi)
  - Mass Spectrometry Center (Dale Whittington)

9:30 – 10:15 a.m. Meeting with School of Pharmacy Advisory Board
Teleconference with selected members of our School’s Corporate Advisory Board (TBD)

10:15 – 11:00 a.m. Review Committee Executive Session

11:00 – 11:45 a.m. Lunch (*or extended working session if the committee would like)

11:45 – 12:00 p.m. Review Committee meeting with Graduate School Representative to discuss preliminary recommendations
Exit Discussion

Unit Representative (exit at 12:30 p.m.)
Andy Stergachis, Associate Dean for Research, Graduate Programs, and New Initiatives

University Administrators (assembled by the Graduate School)
Sean D. Sullivan, Dean, School of Pharmacy
Kima Cargill, Associate Dean for Academic Affairs, Graduate School
Patricia Moy, Associate Vice Provost for Academic and Student Affairs
Becky Corriell, Director, Academic Program Review & Strategy, Graduate School
Layla Tavassoli, Specialist, Academic Affairs & Planning, Graduate School
Anirban Basu, School of Pharmacy Graduate School Council Representative
Anne Hirsch, Graduate School Council Representative
Kalei Kanuha, Graduate School Council Representative